Arvinas, Inc. Files 8-K Report
Ticker: ARVN · Form: 8-K · Filed: Nov 19, 2024 · CIK: 1655759
| Field | Detail |
|---|---|
| Company | Arvinas, Inc. (ARVN) |
| Form Type | 8-K |
| Filed Date | Nov 19, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k
Related Tickers: ARVN
TL;DR
ARVN filed an 8-K, no major news yet.
AI Summary
On November 18, 2024, Arvinas, Inc. filed an 8-K report to disclose other events. The filing does not contain specific details regarding material events, agreements, or financial transactions, but serves as a notification to the SEC.
Why It Matters
This filing indicates Arvinas, Inc. has submitted a report to the SEC, which could precede or follow other significant corporate announcements.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not disclose any new material information that would inherently increase risk.
Key Players & Entities
- Arvinas, Inc. (company) — Registrant
- 0001655759-24-000137 (document_id) — Accession Number
- 20241118 (date) — Date of earliest event reported
- 203-535-1456 (phone_number) — Registrant's telephone number
FAQ
What is the purpose of this 8-K filing by Arvinas, Inc.?
The purpose of this 8-K filing is to report 'Other Events' as of November 18, 2024, as required by the Securities Exchange Act of 1934.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is November 18, 2024.
What is Arvinas, Inc.'s principal executive office address?
Arvinas, Inc.'s principal executive offices are located at 5 Science Park, 395 Winchester Ave., New Haven, Connecticut 06511.
What is Arvinas, Inc.'s IRS Employer Identification No.?
Arvinas, Inc.'s IRS Employer Identification No. is 47-2566120.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 448 words · 2 min read · ~1 pages · Grade level 11.4 · Accepted 2024-11-18 17:46:31
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share ARVN The Nasdaq Stock Market
Filing Documents
- arvn-20241118.htm (8-K) — 23KB
- 0001655759-24-000137.txt ( ) — 148KB
- arvn-20241118.xsd (EX-101.SCH) — 2KB
- arvn-20241118_lab.xml (EX-101.LAB) — 23KB
- arvn-20241118_pre.xml (EX-101.PRE) — 13KB
- arvn-20241118_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. Arvinas, Inc. (the "Company"), along with Pfizer, Inc., regularly evaluate enrollment and blinded event rates in the ongoing VERITAC-2 Phase 3 second-line clinical trial of vepdegestrant as a monotherapy in patients with metastatic breast cancer. Based on current trial status, which completed enrollment in the fourth quarter of 2024, the primary completion date for this clinical trial has been reprojected from November 2024 to January 2025, with top-line data anticipated in the first quarter of 2025.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARVINAS, INC. Date: November 18 , 2 024 By: /s/ Andrew Saik Andrew Saik Chief Financial Officer